64Cu-FBP8 PET-CT Imaging for Blood Clots

Recruiting in Palo Alto (17 mi)

Overseen byTilo Winkler, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Peter David Caravan

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing a new imaging tool that helps doctors see fresh blood clots in patients with PE and DVT. It uses a special substance that binds to the clots, making them visible on a PET scan. This could improve diagnosis, especially for patients with kidney or lung problems.

Research Team

Tilo Winkler, PhD

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

This trial is for adults over 18 with a recent diagnosis of pulmonary embolism or deep vein thrombosis confirmed by CT scans. Participants must be able to lie flat for 45 minutes and have adequate kidney function. Pregnant women, those exceeding weight limits for PET imaging, or individuals exposed to high levels of radiation in the past year are excluded.

Inclusion Criteria

I am 18 or older and have a confirmed pulmonary embolism.

I received a special injection within 3 days of being diagnosed.

Exclusion Criteria

I cannot lie flat for 45 minutes due to a condition like back pain or arthritis.

My eligibility is not affected by my race, sex, or ethnicity.

I am not pregnant or breastfeeding, confirmed by a test.

See 9 more

Treatment Details

Interventions

64Cu-FBP8 (PET Probe)
PET-CT Imaging (Diagnostic Imaging)

Trial OverviewThe study tests a new PET scan probe called 64Cu-FBP8 designed to detect fresh blood clots in lungs and veins. It aims to see how well this probe works compared to current diagnostic methods within three days of clot diagnosis.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Acute pulmonary embolismExperimental Treatment2 Interventions

Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.